近日,Clinical Lung Cancer发表了一篇非常有趣的治疗个案。患者在PD1耐药后尝试PDL1竟然取得了很好的效果。这种治疗方案并非凭空而来,其实还有一定的细节讲究,一起来看看。 病·例·分·享 基本情况:局晚期TP53突变、PDL1阳性老年患者 患者,女,79岁,吸烟者,...
The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trialsCTLA4 inhibitormeta-analysisnon-small cell lung cancer...
参考文献 1 Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the ...
pdl1分子在肿瘤相关巨噬细胞介导肺癌免疫逃逸中作用-role of pdl 1 molecule in tumor-related macrophage-mediated immune escape from lung cancer.docx,PD- PD-L1 分子在肿瘤相关巨噬细胞介导肺癌免疫逃逸中的作用 中文摘要 PAGE PAGE VII PAGE PAGE VI PD-L1 分子在肿瘤
system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer...
National Cancer Institute NCT06538935/Not yet recruiting临床2期IIT A Phase II, Open-label, Two Arm, Investigator-initiated Trail of Stereotactic Radiotherapy (SBRT) in Combination With an Anti-PD-L1 Inhibitor Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma ...
PDL1 testing in guiding patient selection for PD1/PDL1 inhibitor therapy in lung cancer Mol Diagn Ther, 22 (1) (2018), pp. 1-10, 10.1007/s40291-017-0308-6 View in ScopusGoogle Scholar 8 R Büttner, JR Gosney, BG Skov, et al. Programmed death-ligand 1 immunohistochemistry testing: a...
Timing of immunotherapy in stage IV non-small cell lung cancer. 8544#Background:Excluding oncogene-driven disease, a combination of cytotoxic chemotherapy and immune checkpoint inhibitor (i.e., anti-PD1/PDL1 inhibitors)... T Komiya,J Zhu,S Takamori,... - 《Journal of Clinical Oncology》 被...
9 H i r s c h F R , Mc e l h i n n y A , S t a n f o r t h D, e t a l . P D - L 1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol, 2017, 12(2): 208-222. doi: 10.1016...
1.A Novel Bispecific Antibody Targeting EGFR and cMet is Effective Against EGFR Inhibitor Resistant Lung Tumors. 2. /view/subcutaneous-regimen-shows-equal-efficacy-to-intravenous-in-her2-breast-cancer 3. 4./view/fixed-dose-pertuzumab-trastuzumab-combo-approved-in-europe-for-her2-breast-cancer 声明...